LFWD
Lifeward Ltd. NASDAQ Listed Sep 12, 2014$6.76
Mkt Cap $10.3M
52w Low $4.14
19.2% of range
52w High $17.76
50d MA $6.78
200d MA $7.44
P/E (TTM)
-0.4x
EV/EBITDA
-4.8x
P/B
10.0x
Debt/Equity
0.2x
ROE
-236.8%
P/FCF
-4.8x
RSI (14)
—
ATR (14)
—
Beta
0.16
50d MA
$6.78
200d MA
$7.44
Avg Volume
18.3K
Lifeward Ltd. is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm's exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs. Its products include ReWalk Exo-Suit and ReWalk Personal 6.0. The company was founded by Amit Goffer on June 20, 2001 and is headquartered in Marlborough, MA.
3 Hatnufa Street · Yokneam Illit, MA 2069203 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.84 | -3.60 | -328.6% | 6.72 | +1.0% | +1.5% | -1.2% | -3.9% | -1.4% | +2.2% | — |
| Nov 14, 2025 | AMC | -0.09 | -0.20 | -122.2% | 7.18 | +0.3% | -0.6% | +2.0% | -9.5% | -5.3% | +0.8% | — |
| Aug 14, 2025 | AMC | -0.25 | -0.58 | -132.0% | 7.34 | +1.4% | +3.4% | +1.1% | -3.9% | -0.5% | +0.7% | — |
| May 15, 2025 | AMC | -0.33 | -0.46 | -39.4% | 15.48 | +0.8% | +0.8% | -0.8% | -2.3% | -5.6% | +5.9% | — |
| Mar 7, 2025 | AMC | -0.20 | -0.38 | -90.0% | 19.56 | -9.2% | -19.6% | +10.7% | +1.4% | +8.8% | -5.6% | — |
| Nov 12, 2024 | AMC | -0.27 | -0.45 | -66.7% | 28.68 | +0.0% | -16.3% | -3.0% | -7.2% | -2.8% | +5.1% | — |
| Aug 14, 2024 | AMC | -0.55 | -0.50 | +9.1% | 37.44 | -2.9% | +30.4% | -8.6% | -0.5% | -0.5% | +0.3% | — |
| May 15, 2024 | AMC | -0.70 | -0.73 | -4.3% | 60.60 | -0.2% | +0.2% | +0.0% | -1.2% | +1.4% | -1.2% | — |
| Feb 27, 2024 | AMC | -0.91 | -0.35 | +61.5% | 78.12 | +0.0% | -3.7% | +4.5% | +2.1% | +2.5% | -15.3% | — |
| Nov 14, 2023 | AMC | -0.11 | -0.13 | -18.2% | 60.36 | +3.0% | +1.6% | +3.9% | -1.1% | -2.7% | +0.0% | — |
| Jun 30, 2023 | AMC | -0.49 | -0.55 | -11.4% | 50.40 | +5.0% | +16.7% | +11.2% | -2.4% | +2.6% | +6.4% | — |
| Mar 31, 2023 | AMC | -0.56 | -0.51 | +9.2% | 60.48 | +0.0% | -4.2% | -0.6% | +2.1% | -3.9% | -1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.72 | $6.79 | +1.0% | +1.5% | -1.2% | -3.9% | -1.4% | +2.2% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.14 | $7.14 | +0.0% | +2.0% | -9.5% | -5.3% | +0.8% | +10.8% |
| Mar 11 | Lake Street | Maintains | Buy → Buy | — | $15.72 | $15.72 | +0.0% | +10.7% | +1.4% | +8.8% | -5.6% | +5.3% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.72 | $15.72 | +0.0% | +10.7% | +1.4% | +8.8% | -5.6% | +5.3% |
| Feb 20 | Lake Street | Maintains | Buy → Buy | — | $22.08 | $22.20 | +0.5% | +0.0% | -3.8% | -8.5% | -0.6% | +6.2% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.08 | $22.20 | +0.5% | +0.0% | -3.8% | -8.5% | -0.6% | +6.2% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.68 | $28.68 | +0.0% | -16.3% | -3.0% | -7.2% | -2.8% | +5.1% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.84 | $49.32 | +1.0% | -8.6% | -0.5% | -0.5% | +0.3% | -4.9% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $60.60 | $60.48 | -0.2% | +0.2% | +0.0% | -1.2% | +1.4% | -1.2% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $64.32 | $65.40 | +1.7% | -6.7% | -0.2% | +0.2% | -0.4% | -4.0% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $78.12 | $78.12 | +0.0% | -3.7% | +4.5% | +2.1% | +2.5% | -15.3% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $60.36 | $62.16 | +3.0% | +1.6% | +3.9% | -1.1% | -2.7% | +0.0% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.16 | $58.08 | -1.8% | -3.7% | -6.9% | -3.4% | +1.6% | -1.2% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $58.44 | $58.08 | -0.6% | +3.3% | -2.0% | -3.7% | -6.9% | -3.4% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.40 | $52.92 | +5.0% | +16.7% | +11.2% | -2.4% | +2.6% | +6.4% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.08 | $52.08 | +0.0% | -1.4% | +1.9% | -2.5% | +0.2% | -0.2% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $73.20 | $73.92 | +1.0% | +0.5% | +4.2% | -4.7% | +5.1% | -3.1% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $88.20 | $86.52 | -1.9% | -1.9% | +2.9% | +0.9% | +5.2% | -2.3% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $222.60 | $246.12 | +10.6% | +8.7% | +8.0% | +2.6% | -11.3% | -4.2% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $105.84 | $109.20 | +3.2% | +0.8% | +0.0% | +1.6% | +2.0% | +0.3% |
| Jun 17 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $437.64 | $464.52 | +6.1% | -1.3% | -8.4% | +1.3% | -3.1% | -2.6% |
| Nov 3 | Jefferies | Maintains | Buy → Buy | — | $2835.00 | $2940.00 | +3.7% | +3.7% | +1.8% | +0.0% | +1.8% | -5.2% |
| Aug 4 | Canaccord Genuity | Maintains | Buy → Buy | — | $3150.00 | $3150.00 | +0.0% | +3.3% | -6.5% | +0.0% | -6.9% | +0.0% |
| Apr 3 | Barclays | Downgrade | Equal Weight → Underweight | — | $4410.00 | $4200.00 | -4.8% | -2.4% | -7.3% | +0.0% | +2.6% | +0.0% |
| Dec 18 | Barclays | Maintains | Equal Weight → Equal Weight | — | $23100.00 | $23562.00 | +2.0% | +22.7% | +0.8% | +5.6% | +16.4% | +1.0% |
| Aug 7 | Jefferies | Maintains | Buy → Buy | — | $19446.00 | $19320.00 | -0.6% | +0.9% | +2.8% | -4.1% | +2.6% | +0.0% |
| May 22 | Canaccord Genuity | Upgrade | Hold → Buy | — | $23226.00 | $24759.00 | +6.6% | +20.7% | +1.9% | -4.5% | -1.6% | -1.5% |
| May 8 | Barclays | Maintains | Equal Weight → Equal Weight | — | $23499.00 | $23520.00 | +0.1% | -4.7% | +0.7% | +5.2% | -0.4% | -0.5% |
| May 8 | Jefferies | Maintains | Buy → Buy | — | $23499.00 | $23520.00 | +0.1% | -4.7% | +0.7% | +5.2% | -0.4% | -0.5% |
No insider trades available.
8-K
Lifeward Ltd. -- 8-K Filing
I cannot provide a meaningful investor analysis based on this filing summary, as it contains only technical XBRL metadata and regulatory references rather than substantive business information about Lifeward Ltd.
Apr 23
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis from this filing abstract, as it contains only technical XBRL metadata and references without disclosing any material business events, financial results, or corporate actions that would impact LFWD's stock valuation.
Mar 31
8-K
Unknown — 8-K Filing
Lifeward is transferring its acquisition obligations to Oratech Ltd, potentially signaling financial constraints or strategic pivot that could delay or derail the original deal's value creation.
Mar 25
8-K
Unknown — 8-K Filing
LFWD's continued Nasdaq listing despite potential delisting risk signals regulatory compliance, maintaining market access critical for fundraising and shareholder liquidity.
Mar 20
8-K
Unknown — 8-K Filing
Unable to provide analysis—the filing excerpt contains only signature pages without material disclosures about LFWD's business, financial results, or corporate events needed to assess stock impact.
Mar 18
8-K
Unknown — 8-K Filing
Oramed's acquisition of Oratech and related securities purchase agreement signal management confidence in growth strategy, potentially diluting existing shareholders but expanding pipeline assets that could drive future revenue.
Mar 13
8-K
Unknown — 8-K Filing
This 8-K filing indicates LFWD has provided updated regulatory disclosures, likely signaling emerging growth company status changes that could affect financial reporting requirements and investor protections.
Mar 11
8-K
Lifeward Ltd. -- 8-K Filing
Lifeward Ltd. will implement a reverse stock split effective February 24, 2026, and increase authorized shares to 100 million, with the split also applying to warrants and options.
Mar 2
8-K
Lifeward Ltd. -- 8-K Filing
I cannot provide a meaningful analysis because this filing summary contains technical SEC metadata rather than substantive business information about Lifeward Ltd.
Feb 27
8-K
Lifeward Ltd. -- 8-K Filing
Lifeward Ltd. agreed to a Section 4(a)(2) private securities transaction with Skelable, involving standard representations, warranties, and customary closing conditions for an unspecified investment amount.
Feb 25
8-K · 1.01
!! High
Lifeward Ltd. -- 8-K 1.01: Material Agreement
Lifeward Ltd. entered a $3.0 million agreement with Oramed Ltd., potentially expanding its pharmaceutical partnerships and revenue opportunities through this material collaboration.
Feb 19
8-K · 8.01
!! High
Lifeward Ltd. -- 8-K 8.01: Material Event / Announcement
Lifeward Ltd. failed to regain compliance with Nasdaq's minimum bid price requirement by the February 2, 2026 deadline, putting the company at risk of delisting from the exchange.
Feb 9
Data updated apr 25, 2026 6:58pm
· Source: massive.com